Skip to main content
Premium Trial:

Request an Annual Quote

Michael Vicari

OncoCyte has appointed Michael Vicari to a newly created position of vice president of sales, in which he will report directly to president and CEO William Annett. In his new role, Vicari will be responsible for the development and successful implementation of domestic and international sales strategies for OncoCyte, with an initial focus on the expected fourth quarter US launch of the firm's liquid biopsy lung cancer test DetermaVu.

Vicari comes with 35 years of successful sales and marketing leadership within the healthcare industry, including the launch of several important diagnostic products, OncoCyte said. He previously worked with Eurofins Scientific as VP of sales & marketing for the company's clinical diagnostics business. Prior to Eurofins, he was VP of sales for Sequenom, for Monogram Biosciences, and served in senior commercial leadership roles at Genentech, Corixa Oncology, and MedImmune.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.